Research To Practice | Oncology Videos

Featuring perspectives from Dr Robin "Katie" Kelley, including the following topics: Introduction (0:00) Case: A man in his mid 80s with newly diagnosed hepatocellular carcinoma (HCC) who has a partial response with atezolizumab/bevacizumab — Minesh Dinubhai Patel, MD (15:01) Case: A man in his mid 60s with HCC and lung metastases (AFP = 30,000) who receives front-line atezolizumab/bevacizumab — Warren S Brenner, MD (30:17) Case: A man in his mid 60s with metastatic HCC and rapid disease progression on first-line atezolizumab/bevacizumab — Shaachi Gupta, MD, MPH (34:56) Case: A man in his early 80s with NASH liver cirrhosis and advanced HCC who develops proteinuria on atezolizumab/bevacizumab — Liudmila N Schafer, MD (39:09) Journal Club with Dr Kelley (42:53) Case: A woman in her early 70s with metastatic pancreaticobiliary cancer thought to be intrahepatic cholangiocarcinoma — Priya Rudolph, MD, PhD (48:39) Case: A woman in her late 40s with intrahepatic cholangiocarcinoma and micrometastases in portal lymph nodes — Pavel A Levin, MD, PhD (59:13) CME information and select publications

Featuring an interview with Dr Brian Slomovitz, including the following topics: Comparative efficacy and safety of commercially available PARP inhibitors for ovarian cancer (OC) (0:00) Patient- and disease-specific considerations in the selection and sequencing of treatment for OC with BRCA mutations (11:39) Mechanism of action of mirvetuximab soravtansine; recent efficacy and safety data with mirvetuximab for platinum-resistant OC from the SORAYA trial (15:13) Potential integration of mirvetuximab soravtansine into the treatment algorithm for platinum-resistant OC; emerging data with niraparib/dostarlimab and adavosertib for OC (20:23) Ongoing clinical trials evaluating tumor treating fields and upifitamab rilsodotin for OC (24:57) Recent follow-up data with pembrolizumab/bevacizumab/chemotherapy for metastatic cervical cancer (CC) from the KEYNOTE-826 trial (27:30) Efficacy and safety data with lenvatinib/pembrolizumab from the KEYNOTE-775 trial for endometrial cancer (EC); benefit of lenvatinib/pembrolizumab in subsequent lines of therapy (32:13) Updated data with dostarlimab for microsatellite instability (MSI)-high EC; ongoing clinical trials evaluating immunotherapy versus chemotherapy alone for MSI-high EC (35:47) HER2-low data with T-DXd for breast cancer and its potential role in therapy for EC; emerging role of mTOR inhibitors; ongoing investigations and unmet needs in OC, CC and EC (40:01) CME information and select publications

Featuring a slide presentation and related discussion from Dr Brian Slomovitz, including the following topics: Recent data with PARP inhibitors alone and in combination with other agents as maintenance therapy for advanced ovarian cancer; recent data with novel agents (0:00) Efficacy data with pembrolizumab/chemotherapy from the KEYNOTE-826 trial; biologic rationale for targeting tissue factor and emerging data with tisotumab vedotin for cervical cancer (16:45) PFS2 data (disease progression on next line of therapy after first progression) with lenvatinib/pembrolizumab for advanced endometrial cancer; recent data with dostarlimab and mTOR inhibitors (23:58) CME information and select publications

Featuring perspectives from Dr Samuel Klempner, including the following topics: Introduction (0:00) Case: A man in his mid 70s with gastric adenocarcinoma and oligometastatic disease to the liver (PD-L1 10%, HER2-positive) — Ranju Gupta, MD (2:47) Case: A man in his early 70s with locally advanced HER2-positive gastroesophageal junction (GEJ) adenocarcinoma who undergoes chemoradiation therapy and surgery but develops progressive disease on adjuvant nivolumab and is now receiving CAPOX with trastuzumab (PD-L1 10%, microsatellite stable [MSS]) — Bruce Bank, MD (9:39) Treatment of Microsatellite Instability-High Disease (20:46) Case: A woman in her late 60s with GEJ adenocarcinoma metastatic to the liver (MSS, PD-L1 2%, HER2-negative) — Warren S Brenner, MD (36:32) Case: A man in his late 50s with GEJ adenocarcinoma who receives neoadjuvant fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT), is found to have 8/18 positive nodes at surgery, receives adjuvant FLOT and currently has no evidence of disease (PD-L1 Case: A man in his early 50s with esophageal adenocarcinoma with an FDG-avid mediastinal node who undergoes chemoradiation therapy and definitive radiation therapy to the node (MSS, PD-L1 0%, HER2-negative) — Jennifer L Dallas, MD (48:55) Case: A man in his mid 50s with a history of Barrett's esophagus with T1bNXM0 adenocarcinoma with signet cell features who undergoes endoscopic resection and declines esophagectomy — Matthew R Strickland, MD (53:11) Case: A man in his early 60s with a 70-lb weight loss and locally advanced high-grade neuroendocrine carcinoma of the distal esophagus — Dr Gupta (56:58) CME information and select publications

Featuring an interview with Dr Ezra Cohen, including the following topics: Spectrum of targetable mutations in thyroid cancer and impact on treatment selection (0:00) Comparative efficacy of TRK inhibitors in patients with thyroid cancer, including those with CNS disease (6:06) Current and emerging roles of immunotherapy alone and in combination with tyrosine kinase inhibitors for patients with head and neck cancer (10:17) Predicting clinical response to immunotherapy for patients with head and neck cancers (19:47) Role of dose reduction in managing toxicities associated with immunotherapy and targeted agents (26:01) Current and potential roles for cell-free DNA testing and minimal residual disease assessment in the management of head and neck cancer (32:08) Recently reported efficacy data with avasopasem in the treatment of radiation-induced oral mucositis (35:27) Factors affecting response to immunotherapy (42:07) CME information and select publications

Featuring a slide presentation and related discussion from Dr Ezra Cohen, including the following topics: Current standard therapy for head and neck cancer (0:00) Emerging data from clinical trials in head and neck cancer (3:41) Current standard therapy and recent research data in thyroid cancer (15:35) CME information and select publications

Featuring perspectives from Dr Daniel DeAngelo, including the following topics: Introduction: Perspectives on chronic myeloid leukemia (CML) (0:00) Asciminib — ASC4FIRST study (8:33) Case: A woman in her early 60s with a PMH of Stage IA hormone receptor-positive breast cancer on adjuvant tamoxifen with newly diagnosed CML — Michael R Grunwald, MD (22:38) Case: A man in his mid 40s with low-risk CML who achieves MR4 on imatinib but loses molecular response 3 months after discontinuing therapy — Shams Bufalino, MD (27:23) Case: A man in his early 40s with CML on dasatinib who does not achieve treatment milestone (MR3) at 18 months but does at 24 months — Dr Grunwald (33:19) Case: A man in his early 80s with CML who initially receives imatinib followed by nilotinib develops CHF and has a BCR-ABL of 0.8% (IS) — Namrata I Peswani, MD (37:33) Case: A woman in her late 20s with CML that is resistant to multiple TKIs and therapy compliance concerns — Minesh Dinubhai Patel, MD (40:44) Case: A woman in her early 40s who initially receives dasatinib for chronic-phase CML with a good response but then develops lymphoid blast crisis — Dr Grunwald (52:17) Case: A woman in her mid 70s with CML who achieves MMR on nilotinib but then develops peripheral arterial occlusion after 9 years on therapy — Dr Grunwald (58:10) CME information and select publications

Featuring perspectives from Dr Ursula Matulonis, including the following topics: Introduction: Journal Club with Ursula Matulonis, MD — Part 1 (0:00) Case: A woman in her late 60s with primary peritoneal carcinoma with a germline BRCA mutation who underwent naturopathic therapy — Dana M Chase, MD (31:08) Case: A woman in her late 70s with Stage IIIC fallopian tube cancer (homologous recombination proficient [HRp]) who underwent neoadjuvant chemotherapy — Paul DiSilvestro, MD (33:55) Case: A woman in her late 60s with high-grade serous ovarian carcinoma and extensive peritoneal and omental metastases (HRp) who received chemotherapy and bevacizumab followed by niraparib — Vikas Malhotra, MD (38:50) Case: A woman in her mid 70s with a germline BRCA1 mutation and bilateral breast cancer who experiences a complete response for 8 years to chemotherapy for metastatic ovarian cancer — Bruce Bank, MD (46:38) Faculty Survey (49:46) Journal Club with Dr Matulonis — Part 2 (54:02) Case: A woman in her mid 40s who experienced multiple relapses of microsatellite instability-high clear cell ovarian cancer — Syed F Zafar, MD (57:38) CME information and select publications

Efficacy data with T-DXd from the DESTINY-Breast04 trial for patients with HER2-low breast cancer; incidence and biologic relevance of HER2 mutations in breast cancer (0:00) Current and potential clinical roles for liquid biopsy in breast cancer; cardiac toxicity with T-DXd in the DESTINY-Breast04 trial (6:10) Safety profile of T-DXd from the DESTINY-Breast04 trial (11:09) Incidence and management of interstitial lung disease caused by T-DXd (14:54) Disease- and patient-specific factors and other considerations in the sequencing of chemotherapy, antibody-drug conjugates, tyrosine kinase inhibitors, SERDs (selective estrogen receptor degraders) and CDK4/6 inhibitors for breast cancer (21:45) Case: A woman in her early 60s with new lobular Stage II breast cancer 20 years after previous breast cancer on the same side (28:39) Case: A woman in her late 20s with a right breast lump and a strong family history of breast cancer (36:12) Case: A woman in her late 30s presenting with right axillary pain who experiences disease progression on T-DM1 and then receives T-DXd (46:09) Future of novel antibody-drug conjugates alone and in combination with immunotherapy for breast cancer (52:35) CME information and select publications

Featuring a slide presentation and related discussion from Dr Shanu Modi, incluing the following topics: Biology and incidence of HER2-low breast cancer (0:00) Emerging clinical trial data with targeted therapies for HER2-low breast cancer (4:53) Future directions in the treatment of HER2-low breast cancer (16:58) CME information and select publications